# Youssef Bennani

> Youssef Bennani is a Series B investor at CTI Life Sciences Fund backing Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [CTI Life Sciences Fund](https://shizune.co/investors/profile/cti-life-sciences-fund-2)
- Total investments: 3
- Last investment: Dec 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/youssef-bennani-5240144/

Youssef Bennani is a Series B investor at CTI Life Sciences Fund focused on Biotechnology and Pharmaceutical. Youssef Bennani is based out of Canada, and is the Managing Partner at CTI Life Sciences Fund and Board of Director at Aeovian Pharmaceuticals. Youssef previously served as the Chief Scientific Officer at adMare Bio Innovations. Youssef Bennani attended the Université de Montréal.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 33% |
| Series C | 1 | 33% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M | Series B | Dec 16, 2025 |  |
| Oligon | Oligon company provides emerging biotechnology services developing a novel class of multimodal RNA therapeutics. They provide RNA oligonucleotide consultants, research associates, and research scientists. Their contact is done through phone and email. | $14M |  | Sep 23, 2025 |  |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M | Series C | Apr 16, 2025 |  |

3 of 3 investments shown.

## Co-investors
- [The TSC Alliance Endowment Fund](https://shizune.co/investors/profile/the-tsc-alliance-endowment-fund) — VC Fund, 3 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 1 deal together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 1 deal together
- [Asahi Kasei Corporate Venture Capital](https://shizune.co/investors/profile/asahi-kasei-corporate-venture-capital) — VC Fund, 1 deal together
- [Chiesi Ventures](https://shizune.co/investors/profile/chiesi-ventures) — VC Fund, 1 deal together

## About CTI Life Sciences Fund

VC Fund · Montréal, Canada

CTI Life Sciences, a Canadian venture firm makes venture capital investments in high quality emerging life sciences companies at the pre-clinical and clinical development stage in Canada and in the U.S. CTI Life Sciences currently manage $345 million of assets.

4 contacts available at CTI Life Sciences Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Youssef Bennani | Managing Partner | https://shizune.co/investors/profile/youssef-bennani-d1a3 |
| Jean-Francois Leprince | Managing Partner | https://shizune.co/investors/profile/jean-francois-leprince |
| Ken Pastor | General Partner | https://shizune.co/investors/profile/ken-pastor |
| Shermaine Tilley | Managing Partner | https://shizune.co/investors/profile/dr-shermaine-tilley |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Youssef Bennani invest in?

Youssef Bennani invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Youssef Bennani last invest?

The most recent investment recorded for Youssef Bennani closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co